. 2022 Aug 10;40(6):1263–1273. doi: 10.1007/s10637-022-01281-z

Table 2.

Treatment-related adverse events (> 10% of patients) and laboratory abnormalities (hematological and biochemical) at the recommended dose for phase II studies, with or without BEV

	Group A (Paclitaxel 80 mg/m² / lurbinectedin 4.0 mg FD or 2.2 mg/m²) (n = 37)				Group B (Paclitaxel 80 mg/m² / lurbinectedin 2.2 mg/m² / BEV 15 mg/kg) (n = 12)
NCI-CTCAE grade	1–2	3	4	Total	1–2	3	4	Total
Hematological laboratory abnormalities
Anemia ^a	72	22		94	83	17		100
Neutropenia ^a	14	31	28	72		42	25	67
Thrombocytopenia ^a	31	17		47	25	17		42
Biochemical laboratory abnormalities
ALT increased ^a	47	11	3	61	75			75
AP increased ^a	36	6		42	42			42
AST increased ^a	44	6	3	53	42			42
Bilirubin increased ^a	11	3		14
CPK increased ^a	11			11	17			17
Creatinine increased ^a	81			81	75			75
Adverse events
Abdominal abscess						17		17
Alopecia	24			24	42			42
Constipation	8			8	25			25
Decreased appetite	16			16	25			25
Diarrhea	22	3		24	33			33
Dysgeusia	11			11
Dyspepsia	11			11	17			17
Epistaxis					17			17
Fatigue	57	3		59	50	8		58
Febrile neutropenia		3		3		17		17
Hypertension					25			25
Nausea	51	3		54	50			50
Peripheral sensory neuropathy	27			27	17			17
Pulmonary embolism						17		17
Rash maculo-papular	3	3		5	17			17
Vomiting	43	3		46	8			8

The percentage of patients with each adverse event is specified

Hematological and biochemical abnormalities are shown regardless of relationship to treatment

^a Missing data for one patient in Group A

ALT alanine aminotransferase, AP alkaline phosphatase, AST aspartate aminotransferase, BEV bevacizumab, CPK creatine phosphokinase, FD flat dose, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events